JP2020507624A - スルフィニルピリジンおよび癌の治療におけるそれらの使用 - Google Patents

スルフィニルピリジンおよび癌の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2020507624A
JP2020507624A JP2019563696A JP2019563696A JP2020507624A JP 2020507624 A JP2020507624 A JP 2020507624A JP 2019563696 A JP2019563696 A JP 2019563696A JP 2019563696 A JP2019563696 A JP 2019563696A JP 2020507624 A JP2020507624 A JP 2020507624A
Authority
JP
Japan
Prior art keywords
independently
optionally substituted
cancer
compound
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507624A5 (enExample
Inventor
ベンジャミン・ペルクマン
オーヴェ・オーヴァル
ヴィリアム・スタッフォード
ケル・アンデション
Original Assignee
オブリーク セラピューティクス アーベー
オブリーク セラピューティクス アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブリーク セラピューティクス アーベー, オブリーク セラピューティクス アーベー filed Critical オブリーク セラピューティクス アーベー
Publication of JP2020507624A publication Critical patent/JP2020507624A/ja
Publication of JP2020507624A5 publication Critical patent/JP2020507624A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2019563696A 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用 Pending JP2020507624A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
US62/455,645 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020507624A true JP2020507624A (ja) 2020-03-12
JP2020507624A5 JP2020507624A5 (enExample) 2021-03-11

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563696A Pending JP2020507624A (ja) 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用

Country Status (12)

Country Link
US (2) US11208384B2 (enExample)
EP (1) EP3580204A1 (enExample)
JP (1) JP2020507624A (enExample)
KR (1) KR20190115011A (enExample)
CN (1) CN110382465A (enExample)
AU (1) AU2018218518B2 (enExample)
BR (1) BR112019016258A2 (enExample)
CA (1) CA3051644A1 (enExample)
MA (1) MA47450A (enExample)
MX (1) MX2019009356A (enExample)
RU (1) RU2019127896A (enExample)
WO (1) WO2018146468A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
KR20190115011A (ko) * 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 설피닐피리딘 및 암의 치료에서 이의 용도
CA3051538A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47458A (fr) * 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
CN111867587A (zh) * 2018-02-12 2020-10-30 信达制药公司 用于治疗癌症的硫氧还蛋白还原酶抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01305064A (ja) * 1988-04-13 1989-12-08 Bayer Ag ２―フエニルスルフイニル―ニトロ―ピリジン類
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
WO2007137255A2 (en) * 2006-05-22 2007-11-29 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE4643T1 (de) 1979-12-19 1983-09-15 Duphar International Research B.V Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen.
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
AU6926596A (en) 1995-08-24 1997-03-19 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
JP2002507197A (ja) 1997-05-30 2002-03-05 ビーエーエスエフ アクチェンゲゼルシャフト 置換チオピリジン
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
JP2009535307A (ja) 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
WO2010138820A2 (en) * 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9206125B2 (en) 2010-02-10 2015-12-08 Public University Corporation Yokohama City University Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
US9539256B2 (en) 2012-02-10 2017-01-10 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACS)
JP6393322B2 (ja) 2013-07-10 2018-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CA3051538A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
KR20190115011A (ko) * 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 설피닐피리딘 및 암의 치료에서 이의 용도
MA47458A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01305064A (ja) * 1988-04-13 1989-12-08 Bayer Ag ２―フエニルスルフイニル―ニトロ―ピリジン類
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
WO2007137255A2 (en) * 2006-05-22 2007-11-29 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORGANIC LETTERS, vol. 13, no. 1, JPN6021049084, 2011, pages 102 - 105, ISSN: 0004660643 *

Also Published As

Publication number Publication date
CN110382465A (zh) 2019-10-25
EP3580204A1 (en) 2019-12-18
KR20190115011A (ko) 2019-10-10
AU2018218518A1 (en) 2019-08-15
US11208384B2 (en) 2021-12-28
US20220177430A1 (en) 2022-06-09
BR112019016258A2 (pt) 2020-04-07
WO2018146468A1 (en) 2018-08-16
US20200024233A1 (en) 2020-01-23
RU2019127896A (ru) 2021-03-09
RU2019127896A3 (enExample) 2021-05-18
CA3051644A1 (en) 2018-08-16
MA47450A (fr) 2019-12-18
MX2019009356A (es) 2019-09-19
AU2018218518B2 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
JP2020507624A (ja) スルフィニルピリジンおよび癌の治療におけるそれらの使用
JP2020506244A (ja) ヘテロシクリルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
JP6636153B2 (ja) ピリジン及び癌治療におけるそれらの使用
JP7229176B2 (ja) ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
US11028067B2 (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11110089B2 (en) Pyridazinones and their use in the treatment of cancer
RU2772935C2 (ru) Гетероарилсульфонил-замещенные пиридины и их применение при лечении рака
RU2777596C2 (ru) Гетероциклилсульфонил-замещенные пиридины и их применение при лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220801